Trailing-twelve-month (TTM) revenue is $746.16 Million with a year-over-year growth of +5.71%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $179,516,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $196,873,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $177,376,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-30 |
| Q2 FY2026Period ended 2026-06-30 | $192,399,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-04 |
| TTM revenue | $746,164,000 |
Current P/S: $973,934,600 market capitalization ÷ $746,164,000 TTM revenue = 1.31x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $192.40M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T21:38:02.817Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Bupivacaine Liposome Injectable Suspension | N/A | $4M | $6M | $3M | $7M | $7M |
| EXPAREL | N/A | $507M | $537M |
$746.16M
$746.16 Million
+5.71%
vs. $705.86M a year ago (TTM)
+8.20%
5 Year compound annual growth rate
1 Year
+5.71%
3 Year
+3.69%
5 Year
+8.20%
10 Year
+10.84%
15 Year
+30.21%
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $726.41M | +$25.45M | +3.63% |
| 2024 | $700.97M | +$25.99M | +3.85% |
| 2023 | $674.98M | +$8.15M | +1.22% |
| 2022 | $666.82M | +$125.29M | +23.14% |
| 2021 | $541.53M | +$111.89M | +26.04% |
| 2020 |
TTM Growth
+5.71%
3-Year CAGR
+3.69%
5-Year CAGR
+8.20%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T21:38:02.817Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| $538M |
| $549M |
| $575M |
| Product | $427M | N/A | $664M | $672M | $697M | $723M |
|---|
| Royalty | $3M | N/A | N/A | N/A | N/A | N/A |
|---|
| ZILRETTA | N/A | $13M | $106M | $111M | $118M | $117M |
|---|
| $429.65M |
| +$8.62M |
| +2.05% |
| 2019 | $421.03M | +$83.75M | +24.83% |
| 2018 | $337.28M | +$50.65M | +17.67% |
| 2017 | $286.63M | +$10.26M | +3.71% |
| 2016 | $276.37M | +$27.37M | +10.99% |
